Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis

Multiple Sclerosis Journal

Volumn 19, Issue 2, 2013, Pages 179-187

  Sellebjerg, F ^a   Hesse, D ^a   Limborg, S ^a   Lund, H ^b   Sondergaard H B ^a   Krakauer, M ^a   Sorensen P S ^a  

^a University of Copenhagen   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

Author keywords

disease modifying therapies; Glatiramer acetate; immunology

Indexed keywords

BIOLOGICAL MARKER; CD40 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; GADOLINIUM; GLATIRAMER; HLA DRB1 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MONOCYTE; MULTIPLE SCLEROSIS; MYELOID DENDRITIC CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMACYTOID DENDRITIC CELL; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECURRENCE RISK; REGULATORY T LYMPHOCYTE; RELAPSE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TREATMENT RESPONSE;

EID: 84872174912     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512450353     Document Type: Article

References (29)

1. Racke MK, Lovett-Racke AE, et al. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010 ; 74: S25 - S30
2. Farina C, Weber MS, Meinl E, et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 2005 ; 4: 567-575
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 ; 45: 1268-1276
4. Sormani MP, Bruzzi P, Comi G, et al. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Mult Scler. 2005 ; 11: 447-449
5. Farina C, Wagenpfeil S, Hohlfeld R.. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study. J Neurol. 2002 ; 249: 1587-1592
6. Valenzuela RM, Costello K, Chen M, et al. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler. 2007 ; 13: 754-762
7. Wiesemann E, Klatt J, Wenzel C, et al. Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Clin Exp Immunol. 2003 ; 133: 454-460
8. Weder C, Baltariu GM, Wyler KA, et al. Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis. Eur J Neurol. 2005 ; 12: 869-878
9. Michel L, Berthelot L, Pettre S, et al. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest. 2008 ; 118: 3411-3419
10. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010 ; 10: 490-500
11. Krakauer M, Sorensen PS, Sellebjerg F.. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol. 2006 ; 181: 157-164
12. Jensen J, Langkilde AR, Fenst C, et al. CD4 T cell activation and disease activity at onset of multiple sclerosis. J Neuroimmunol. 2004 ; 149: 202-209
13. Jensen J, Langkilde AR, Frederiksen JL, et al. CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment. J Neuroimmunol. 2006 ; 179: 163-172
14. Sellebjerg F, Christiansen M, Jensen J, et al. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol. 2000 ; 7: 281-289
15. Sellebjerg F, Ross C, Koch-Henriksen N, et al. CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. Mult Scler. 2005 ; 11: 641-645
16. Fusco C, Andreone V, Coppola G, et al. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology. 2001 ; 57: 1976-1979
17. Hesse D, Krakauer M, Lund H, et al. Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response. Neurology. 2010 ; 74: 1455-1462
18. Goris A, Walton A, Ban M, et al. A Taqman assay for high-throughput genotyping of the multiple sclerosis-associated HLA-DRB1*1501 allele. Tissue Antigens. 2008 ; 72: 401-403
19. Weber MS, Starck M, Wagenpfeil S, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004 ; 127: 1370-1378
20. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med. 2007 ; 13: 935-943
21. Vieira PL, Heystek HC, Wormmeester J, et al. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol. 2003 ; 170: 4483-4488
22. Sellebjerg F, Hedegaard CJ, Krakauer M, et al. Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Mult Scler. 2012 ; 18: 305-313
23. Gross R, Healy BC, Cepok S, et al. Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 ; 233: 168-174
24. Grossman I, Avidan N, Singer C, et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics. 2007 ; 17: 657-666
25. Sellebjerg F, Krakauer M, Limborg S, et al. Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. PLoS One. 2012 ;:
26. Allie R, Hu L, Mullen KM, et al. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy. Arch Neurol. 2005 ; 62: 889-894
27. Kivisakk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA. 2003 ; 100: 8389-8394
28. Chiarini M, Sottini A, Ghidini C, et al. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate. Mult Scler. 2010 ; 16: 218-227
29. Hong J, Li N, Zhang X, et al. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA. 2005 ; 102: 6449-6454